Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2
Rahima Begum et al. Potential Therapeutic Approach of Melatonin against Omicron and Some Other Variants of SARS-CoV-2 The Omicron variant (B.529) of COVID-19 caused disease outbreaks worldwide because of its contagious and diverse mutations. To reduce these outbreaks, therapeutic drugs and adjuvant vaccines have been applied for the treatment of the disease. However, these drugs […]
Pfizer/BioNTech COVID-19 Omicron-Modified Vaccine Options
Pfizer/BioNTech June 28, 2022 Presentation to the Vaccines and Related Biological Products Advisory Committee
Rapid Rollout of New COVID Boosters with nNo Human Trials – ‘A Tale of Recklessness’
Meryl Nass The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) cooperated to issue Emergency Use Authorizations (EUA) and roll out new, bivalent Pfizer and Moderna COVID-19 vaccines this week, without any human trials, which is unprecedented. There is international coordination regarding bivalent boosters, and a major effort […]
The End of Covid-19 Vaccine Safety Science in America
Toby Rogers On June 28, the FDA decided that henceforth THEY will choose the variants for reformulated Covid-19 shots and NO clinical trials will be conducted to evaluate safety. Because $cience.
FDA Panel Votes to Waive Clinical Trials for New COVID Boosters
Megan Redshaw The U.S. Food and Drug Administration’s (FDA) vaccine advisory panel on Tuesday voted 19 to 2 to recommend new COVID-19 booster shots that include the Omicron variant this fall. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) did not issue guidance on whether additional data would be needed to recommend an updated composition of the primary-series vaccines authorized for […]
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Heba N. Altarawneh et al. No notable differences were observed in the effectiveness against BA.1 and BA.2 of previousinfection, vaccination, and hybrid immunity. Protection from previous infection with variants other than omicron against reinfection was moderate and durable, but protection of primary-series vaccination against infection was negligible by 6 months after the second dose. Recent […]
Omicron Subvariants Escape Antibodies Elicited by Vaccination and BA.2.2 Infection
Lin Yao et al. The BA.1, BA.2, and BA.3 omicron subvariants of SARS-CoV-2 showed similar but substantial resistance to vaccine-induced and infection-induced serum neutralising activity.
